CN106913578A - A kind of Diammonium Glycyrrhizinate ammonium composition medicine - Google Patents
A kind of Diammonium Glycyrrhizinate ammonium composition medicine Download PDFInfo
- Publication number
- CN106913578A CN106913578A CN201510994540.0A CN201510994540A CN106913578A CN 106913578 A CN106913578 A CN 106913578A CN 201510994540 A CN201510994540 A CN 201510994540A CN 106913578 A CN106913578 A CN 106913578A
- Authority
- CN
- China
- Prior art keywords
- diammonium glycyrrhizinate
- ammonium
- composition
- composition medicine
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of Diammonium Glycyrrhizinate ammonium composition medicine, including the ammonium of alpha-liquorice acid two and β-diammonium glycyrrhizinate, the ammonium of the alpha-liquorice acid two accounts for the 65-90% of composition gross mass, and the β-diammonium glycyrrhizinate accounts for the 5-8% of composition gross mass.Diammonium Glycyrrhizinate ammonium composition medicine of the invention can be used in the hepatopathy disease that treatment is caused due to virus, and therapeutic effect is good, has no side effect.
Description
Technical field
The present invention relates to Diammonium Glycyrrhizinate ammonium field, a kind of Diammonium Glycyrrhizinate ammonium group is specifically related to
Compound medicine.
Background technology
Diammonium Glycyrrhizinate ammonium is the third generation extract of glycyrrhiza uralensis fisch active ingredient, with certain
The effect of anti-inflammatory, protection liver plasma membrane and improvement liver function.But single use Diammonium Glycyrrhizinate
Its therapeutic effect of ammonium is limited.
The content of the invention
(1) technical problem to be solved
In view of the shortcomings of the prior art, the present invention provides a kind of for treating liver diseases
Diammonium Glycyrrhizinate ammonium composition medicine.
(2) technical scheme
To reach above-mentioned purpose, the invention provides a kind of Diammonium Glycyrrhizinate ammonium composition medicine,
Including the ammonium of alpha-liquorice acid two and β-diammonium glycyrrhizinate, it is total that the ammonium of the alpha-liquorice acid two accounts for composition
The 65-90% of quality, the β-diammonium glycyrrhizinate accounts for the 5-8% of composition gross mass.
Further, for treating due to the hepatopathy disease that virus causes.
Further, also including monopotassium glycyrrhizunate.
(3) beneficial effect
Diammonium Glycyrrhizinate ammonium composition medicine of the present invention can be used in what treatment was caused due to virus
Hepatopathy disease, therapeutic effect is good, has no side effect.
Specific embodiment
With reference to embodiment, specific embodiment of the invention is described in further detail.
Following examples are used to illustrate the present invention, but are not limited to the scope of the present invention.
A kind of Diammonium Glycyrrhizinate ammonium composition medicine of the invention, including the ammonium of alpha-liquorice acid two and
β-diammonium glycyrrhizinate, the ammonium of the alpha-liquorice acid two accounts for the 65-90% of composition gross mass, described
β-diammonium glycyrrhizinate accounts for the 5-8% of composition gross mass.
In the present embodiment, for treating due to the hepatopathy disease that virus causes.
In the present embodiment, also including monopotassium glycyrrhizunate.
Beneficial effects of the present invention：Can be used in the hepatopathy disease that treatment is caused due to virus,
Therapeutic effect is good, has no side effect.
The above is only the preferred embodiment of the present invention, it is noted that led for this technology
For the those of ordinary skill in domain, on the premise of the technology of the present invention principle is not departed from, can be with
Some improvements and modifications are made, these improvements and modifications also should be regarded as protection scope of the present invention.
Claims (3)
1. a kind of Diammonium Glycyrrhizinate ammonium composition medicine, it is characterised in that including alpha-liquorice acid
Two ammoniums and β-diammonium glycyrrhizinate, the ammonium of the alpha-liquorice acid two account for composition gross mass
65-90%, the β-diammonium glycyrrhizinate accounts for the 5-8% of composition gross mass.
2. Diammonium Glycyrrhizinate ammonium composition medicine as claimed in claim 1, it is characterised in that
For treating due to the hepatopathy disease that virus causes.
3. Diammonium Glycyrrhizinate ammonium composition medicine as claimed in claim 1, it is characterised in that
Also include monopotassium glycyrrhizunate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510994540.0A CN106913578A (en) | 2015-12-25 | 2015-12-25 | A kind of Diammonium Glycyrrhizinate ammonium composition medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510994540.0A CN106913578A (en) | 2015-12-25 | 2015-12-25 | A kind of Diammonium Glycyrrhizinate ammonium composition medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106913578A true CN106913578A (en) | 2017-07-04 |
Family
ID=59456033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510994540.0A Pending CN106913578A (en) | 2015-12-25 | 2015-12-25 | A kind of Diammonium Glycyrrhizinate ammonium composition medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106913578A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022161176A1 (en) * | 2021-01-27 | 2022-08-04 | 四川九章生物科技有限公司 | Use of injection composition containing chlorogenic acid in preparation of injection having skin whitening effect |
-
2015
- 2015-12-25 CN CN201510994540.0A patent/CN106913578A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022161176A1 (en) * | 2021-01-27 | 2022-08-04 | 四川九章生物科技有限公司 | Use of injection composition containing chlorogenic acid in preparation of injection having skin whitening effect |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290556A1 (en) | ORAL MEDICAL FORM, INCLUDING ENTEKAVIR | |
| CN106913578A (en) | A kind of Diammonium Glycyrrhizinate ammonium composition medicine | |
| CN104547893A (en) | Medicament for promoting blood circulation and diminishing swelling | |
| CN106913577A (en) | A kind of new Diammonium Glycyrrhizinate ammonium composition medicine | |
| CN103877407B (en) | One treats hypertensive Chinese medicine formula composition and instructions of taking thereof | |
| CN106728359A (en) | Control the Chinese medicine preparation of delayed menstrual cycle | |
| CN104127610A (en) | Medicine for expelling rheumatism | |
| CN103656368A (en) | Medicinal liquor for treating psoriasis | |
| CN107412597A (en) | A kind of Chinese medicine blood-sugar reducing tea for curing diabetes | |
| CN103877528A (en) | Varicella treatment concentrate | |
| CN106581427A (en) | Traditional Chinese medicine preparation for treating beriberi | |
| CN104399032A (en) | Traditional Chinese medicine composition for treating acute nephritis | |
| CN103768155A (en) | Traditional Chinese medicine decoction for preventing influenza | |
| CN106692441A (en) | Pure traditional Chinese medicinal oral liquid for treating sclerosis | |
| CN103656283A (en) | Traditional Chinese medicine liver-protecting tea | |
| CN104257921A (en) | Drug for removing freckles | |
| CN103860703A (en) | Hepatitis treatment compound | |
| CN102451402A (en) | Antitumor medicinal liquor | |
| CN110522856A (en) | Pharmaceutical composition with analgesic efficacy | |
| CN101904896A (en) | Medicament for treating female uterine prolapse disease | |
| MX2019006548A (en) | Composition for the treatment of osteoarthritis. | |
| CN107714784A (en) | A kind of parotitis plaster | |
| CN106474477A (en) | A kind of detumescence spray | |
| CN107260875A (en) | Treat the pure Chinese medicine pill of scleroderma | |
| CN109692213A (en) | The drug of chronic heart failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170704 |